BIOMAT Database Logo BIOMAT Database Logo

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. 1993

R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Department of Neurology, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA 19107.

A pilot study was undertaken to test the safety and establish the side effect profile of recombinant human interferon-beta 1b (Betaseron, Berlex Laboratories, Richmond, CA), in patients with relapsing-remitting multiple sclerosis (RRMS). During the initial dose finding period (24 weeks), five groups of 6 patients each were treated by subcutaneous injection three times each week with either 0.8, 4, 8, or 16 million units (mU) of Betaseron or placebo (WHO Standard). Although some side effects were noted in all groups, a dose-related trend in reduction of exacerbation frequency and side-effect profile was noted. Patients given 16 mU had no exacerbations during the initial dosing period, but associated side effects led to dose reduction or dropout. An 8 mU dose was selected for further study after 24 weeks, and continuous dosing at 8 mU in 15 patients has now exceeded 6 years. Side effects abated over time. Neutralizing antibody developed in most patients, but titers were variable, fluctuated independently of clinical course, and tended to fall with prolonged treatment. A dose-dependent rise in neopterin levels was observed during the initial dosing period. This pilot study has demonstrated responsiveness to Betaseron, shown a stable safety profile over time, and established guidelines for a dosing regimen to evaluate and optimize further the efficacy of Betaseron in RRMS.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004333 Drug Administration Routes The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue. Administration Routes, Drug,Administration Route, Drug,Drug Administration Route,Route, Drug Administration,Routes, Drug Administration

Related Publications

R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
[Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations].
February 2001, Der Nervenarzt,
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study.
June 2009, Acta clinica Croatica,
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.
January 1995, Multiple sclerosis (Houndmills, Basingstoke, England),
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
January 1995, Multiple sclerosis (Houndmills, Basingstoke, England),
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
May 2010, Multiple sclerosis (Houndmills, Basingstoke, England),
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
November 2002, European journal of neurology,
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Interferon-beta in the treatment of relapsing-remitting multiple sclerosis.
October 2003, Pharmacology & therapeutics,
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
July 2002, Clinical neurology and neurosurgery,
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Interferon beta-1a in relapsing-remitting multiple sclerosis.
March 1999, Hospital medicine (London, England : 1998),
R L Knobler, and J I Greenstein, and K P Johnson, and F D Lublin, and H S Panitch, and K Conway, and S V Grant-Gorsen, and J Muldoon, and S G Marcus, and J C Wallenberg
Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis.
March 2001, Journal of neurology, neurosurgery, and psychiatry,
Copied contents to your clipboard!